GlassScriptPhysician profile
Ketan Jani
NPI 1679575054
$2,053.00
in general payments reported to CMS, 2019-2025
25 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $277 · 2021: $458 · 2023: $14.35 · 2024: $421 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618 · Education: $55.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.23 |
| Education | $55.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $745.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $222.19 | 2021-2024 | Airsupra, Tezspire, Fasenra |
| Mylan Specialty L.P. | $123.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.03 | 2019-2021 | |
| Genzyme Corporation | $112.07 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $111.25 | 2019-2020 | |
| Genentech USA, INC. | $81.15 | 2019-2024 | Xolair |
| Harmony Biosciences LLC | $79.93 | 2021-2024 | |
| Inspire Medical Systems, INC. | $75.88 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $62.74 | 2019-2024 | Dupixent |
| Eisai INC. | $45.98 | 2021 | |
| Grifols USA, LLC | $44.47 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $29.39 | 2025 | Lumryz |
| Insmed, INC. | $29.26 | 2025 | Arikayce |
| Zoll Respicardia, INC. | $23.33 | 2024 | Remede System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.27 | 2021 | |
| Axsome Therapeutics, INC. | $21.74 | 2025 | Sunosi |
| Pulmonx Corporation | $16.77 | 2019 | |
| 3b Medical, INC. | $16.49 | 2025 | Luna |
| United Therapeutics Corporation | $15.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.73 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $11.83 | 2019 | |
| Circassia INC. | $10.90 | 2019 | |
| Itamar Medical INC | $7.99 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketan Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.